Dysbiosis
Recent clinical, regulatory, research and industry developments relating to this disease.
Host-pathogen interactions in periodontitis: an integrative interkingdom perspective.
Gut microbiota metabolic reprogramming drives the development of metabolic diseases in the host.
Gut microbiota: a promising new target in immune tolerance.
The Microbiota-Gut-Brain Connection: A New Horizon in Neurological and Neuropsychiatric Disorders.
Type 2 Diabetes and the Multifaceted Gut-X Axes.
Unraveling the Gut-Liver-Brain Axis: Microbiome, Inflammation, and Emerging Therapeutic Approaches.
Gut Microbiota Serves as a Crucial Independent Biomarker in Inflammatory Bowel Disease (IBD).
What's happening now
An analyst briefing on current research, clinical, regulatory and industry activity surrounding this disease.
- 2 clinical trials expected to report results, the earliest in Q4 2028.
- Active recent publication activity.
- 1 industry development reported.
- Q4 2028Synbiotics in Patients at RIsk fOr Preterm Birth: a Multi-center Double-blind Randomized Placebo-controlled trIal
- Q2 2029A Randomised Controlled Trial to Assess if a Probiotic Intervention Leads to Enhanced Immune Responses to Vaccination in Antibiotic-treated Infants (Bloom Infant Probiotic (BIP) Study)
Research HighlightsViewHide
- 2025-09-01The Microbiota-Gut-Brain Connection: A New Horizon in Neurological and Neuropsychiatric Disorders.Faysal M · 2025
- 2026-04-02Host-pathogen interactions in periodontitis: an integrative interkingdom perspective.Suarez LJ · 2026
- 2026-03-14Gut microbiota metabolic reprogramming drives the development of metabolic diseases in the host.Wang Y · 2026
- 2025-09-18Gut microbiota: a promising new target in immune tolerance.Almansour N · 2025
- 2025-09-15Microbiota-gut-brain axis in neurodegenerative diseases: molecular mechanisms and therapeutic targets.Chen C · 2025
- 2025-08-21Type 2 Diabetes and the Multifaceted Gut-X Axes.Guo H · 2025
Clinical MilestonesViewHide
- 2026-05-28A Randomised Controlled Trial to Assess if a Probiotic Intervention Leads to Enhanced Immune Responses to Vaccination in Antibiotic-treated Infants (Bloom Infant Probiotic (BIP) Study)Results expected Q2 2029
- 2026-02-27Synbiotics in Patients at RIsk fOr Preterm Birth: a Multi-center Double-blind Randomized Placebo-controlled trIalResults expected Q4 2028
Industry & MarketViewHide
- 2026-07-25Comprehensive assessment of prometryn bioaccumulation, metabolic fate, and intestinal microbiota dysbiosis in red swamp crayfish (Procambarus clarkii)Industry · Nature — Environmental Sciences
- 2026-07-25IndustryComprehensive assessment of prometryn bioaccumulation, metabolic fate, and intestinal microbiota dysbiosis in red swamp crayfish (Procambarus clarkii)Industry · Nature — Environmental Sciences
- 2026-05-28ClinicalA Randomised Controlled Trial to Assess if a Probiotic Intervention Leads to Enhanced Immune Responses to Vaccination in Antibiotic-treated Infants (Bloom Infant Probiotic (BIP) Study)Results expected Q2 2029
- 2026-04-02ResearchHost-pathogen interactions in periodontitis: an integrative interkingdom perspective.Suarez LJ · 2026
- 2026-03-14ResearchGut microbiota metabolic reprogramming drives the development of metabolic diseases in the host.Wang Y · 2026
- 2026-02-27ClinicalSynbiotics in Patients at RIsk fOr Preterm Birth: a Multi-center Double-blind Randomized Placebo-controlled trIalResults expected Q4 2028
- 2025-10-03ClinicalEffects of Probiotic Supplementation on Disease Progression in Patients With Moderate to Severe Chronic Kidney Disease: A Randomized Controlled TrialPrimary completion
- 2025-09-18ResearchGut microbiota: a promising new target in immune tolerance.Almansour N · 2025
- 2025-09-15ResearchMicrobiota-gut-brain axis in neurodegenerative diseases: molecular mechanisms and therapeutic targets.Chen C · 2025
- 2025-09-01ResearchThe Microbiota-Gut-Brain Connection: A New Horizon in Neurological and Neuropsychiatric Disorders.Faysal M · 2025
- 2025-08-21ResearchType 2 Diabetes and the Multifaceted Gut-X Axes.Guo H · 2025
Research-associated treatments
Drugs and agents co-studied with this disease across the research literature — associative, not necessarily established treatments. Number shows shared papers.
Clinical trials
The current development programme across all trial phases.
Research activity
Key research shaping understanding of this disease, combining the latest publications with the most influential evidence.
Major themes8
- Gastrointestinal Microbiome117
- Dysbiosis39
- Microbiota19
- Probiotics15
- Brain7
- Brain-Gut Axis7
- Alzheimer Disease6
- Diet6
Leading journals6
- International journal of molecular sciences19
- Frontiers in immunology17
- Gut microbes16
- Nutrients15
- Frontiers in cellular and infection microbiology10
- Nature communications6
Leading researchers8
- Chen X7
- Li J5
- Li Y5
- Bäumler AJ4
- Wang Y4
- Zhang J4
- Charitos IA3
- Chen Y3
Affiliations (unnormalised)6
- School of Medicine14
- School of Pharmacy4
- Department of Pathology and Laboratory Medicine3
- Medical University of Lodz3
- School of Life Sciences3
- The First Affiliated Hospital3
Disease biology
Key proteins & gene products studied in this disease. Number shows shared papers.
Related conditions
Diseases frequently studied alongside this one. Number shows shared papers.
Disease profile
A grounded synthesis of the condition — overview, causes, mechanism, risk factors and current standard of care.
Dysbiosis is a change in the quantitative or qualitative composition of the microbiota. These shifts can disturb normal host-microbe interactions and homeostasis, and they are often linked to inflammation and disease states. The literature treats it as a microbiology and pathophysiology concept rather than a single organ-specific disease.
The supplied material supports environmental and genetic factors as contributors to microbiota perturbation. Diet is also identified as an influence on microbiota composition, and the gut-liver axis review notes dietary, genetic, and environmental inputs as relevant to microbial balance. Beyond that, the grounding does not support a more specific aetiology.
Dysbiosis reflects disruption of the normal symbiotic relationship between host and microbiota, with loss of homeostatic balance. The reviews describe downstream effects on immune regulation, colonization resistance, and host microbial interactions, with inflammation as a common consequence. In the gut-brain and gut-liver contexts, altered microbial communities can affect signaling through the immune system, tryptophan metabolism, the vagus nerve, the enteric nervous system, and microbial metabolites.
Environmental factors, genetic factors, and diet are supported as influences that can shift microbiota composition and increase the likelihood of dysbiosis. The literature also indicates that early-life factors can shape microbiota composition, but the supplied abstract is truncated and does not specify which factors. No additional risk factors are supported by the grounding.
The grounding supports microbiota-directed approaches at the class or modality level, including probiotics and synbiotics. It also frames dysbiosis as a target for management or prevention of inflammatory and metabolic disorders, but does not provide specific treatment protocols. No other standard therapies are supported by the supplied material.
AI-generated summary grounded in MeSH and 6 peer-reviewed sources. Informational only — not medical advice. Generated 2026-07-07.
Reference
Authoritative identity, definition & identifiers.
Changes in quantitative and qualitative composition of MICROBIOTA. The changes may lead to altered host microbial interaction or homeostatic imbalance that can contribute to a disease state often with inflammation.
- Disease identity & definition — NLM Medical Subject Headings (MeSH), public domain
- Clinical trials — ClinicalTrials.gov (U.S. National Library of Medicine)
- Research activity — Europe PMC (EMBL-EBI) + OpenAlex-derived paper links
- Related entities are derived from literature co-mention (studied together) — associative, not causal.